[Clinical experimentation of LD 4644 in O.R.L].
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D010879:Piperazines; C008913:pipebuzone; D010653:Phenylbutazone
Expérimentation clinique de LD 4644 en O.R.L